Study on Medication Rules of TCM Treatment for Primary Hepatic Carcinoma in Recent ;Ten Years
10.3969/j.issn.1005-5304.2016.09.011
- VernacularTitle:近10年中医治疗原发性肝癌用药规律研究
- Author:
Minghao LIU
;
Keke LI
;
Lihui ZHANG
;
Hanting JIA
;
Wenxia ZHAO
- Publication Type:Journal Article
- Keywords:
primary hepatic carcinoma;
TCM;
medication rules
- From:
Chinese Journal of Information on Traditional Chinese Medicine
2016;23(9):45-47
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze medication rules of TCM treatment for primary hepatic carcinoma in recent ten years;To provide references for clinical medication. Methods Literature about primary hepatic carcinoma in CNKI, VIP and Wanfang database from January 2005 to September 2015 was searched by computers to carry out statistical analysis of medicine classification and frequency of usage. Results Through screening, 131 articles were included, covering 131 compound TCM prescriptions, 228 kinds of medicine, and 1416 times of frequency of usage. Medicines with relatively high frequency were tonifying deficiency medicine 430 times (30.37%), damp-clearing medicine 233 times (16.45%), medicine for invigorating blood circulation and eliminating stasis (12.99%). Medicines with relatively high frequency were Atractylodis Macrocephalae Rhizoma 64 times (4.52%), Poria 62 times (4.38%), Glycyrrhizae Radix et Rhizoma 52 times (3.67%), Bupleuri Radix 49 times (3.46%), Paeoniae Radix Alba 45 times (3.18%), Astragali Radix 44 times (3.22%), Curcumae Rhizoma 43 times (3.04%), and Artemisiae Scopariae Herba 41 times (2.90%). Conclusion This study summarizes the medicine classification and frequency of usage of TCM treatment for primary hepatic carcinoma in recent ten years, which can provide data support for clinical treatment.
